10-K: American Shared Hospital Services Faces Going Concern Doubt

American Shared Hospital Services reports a net loss for 2025 and faces substantial doubt about its ability to continue as a going concern due to multiple debt covenant defaults.

Summary

• The company reported a net loss attributable to American Shared Hospital Services of $(1,553,000) in 2025, a significant decline from net income of $2,186,000 in 2024.
• Total revenue in 2025 was $28,082,000, a 0.9% decrease from $28,340,000 in 2024.
• Revenue from the leasing segment decreased by $3,076,000 in 2025, primarily due to lower Proton Beam Radiation Therapy (PBRT) volumes and the expiration of three Gamma Knife contracts.
• Direct patient service segment revenue increased by $2,973,000 in 2025, driven by the Puebla, Mexico facility and the three Rhode Island facilities acquired in May 2024.
• Gamma Knife procedures decreased by 13.6% to 937 in 2025 from 1,084 in 2024, mainly due to contract expirations and downtime for equipment upgrades in Peru.
• PBRT procedures decreased by 21.1% to 4,056 in 2025 from 5,139 in 2024, attributed to normal cyclical fluctuations.
• LINAC procedures increased by 92.0% to 28,147 in 2025 from 14,662 in 2024, largely due to the Rhode Island Acquisition and the Puebla facility.
• Costs of revenue increased by $3,863,000 (20.2%) to $23,018,000 in 2025, primarily due to higher operating costs from direct patient service facilities.
• Cash and cash equivalents, including restricted cash, decreased by $7,563,000 to $3,712,000 at December 31, 2025, from $11,275,000 at December 31, 2024.
• The company had a working capital deficit of $5,724,000 at December 31, 2025, compared to a working capital surplus of $15,853,000 at December 31, 2024.
• The company is not in compliance with multiple financial covenants (minimum fixed-charge coverage ratio, maximum funded debt-to-EBITDA ratio, and Minimum Cash Covenant of $5,000,000) under its Credit Agreement with Fifth Third Bank as of September 30, 2025, and December 31, 2025.
• Fifth Third Bank has suspended the Revolving Loan Commitment and has the right to accelerate payment obligations under the Credit Agreement, which matures on April 9, 2026.
• The company's non-compliance with the Credit Agreement could be deemed a cross-default under the DFC Loan, raising substantial doubt about its ability to continue as a going concern.
• A material weakness in internal control over financial reporting was identified as of December 31, 2025, due to insufficient personnel and resources in accounting and finance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to the significant financial covenant defaults, the resulting 'going concern' doubt, and the substantial decline in liquidity and net income. While there are some operational expansions, the financial instability overshadows these positives.

Positives

• LINAC procedure volume increased by 92.0% in 2025, driven by new facilities in Rhode Island and Puebla, Mexico.
• Same-center Gamma Knife procedures increased 11% in 2025, driven by equipment upgrades at two existing customer sites.
• The company successfully acquired a 60% interest in the RI Companies in May 2024, expanding its direct patient service business model in the United States.
• The Puebla, Mexico facility began treating patients in July 2024, contributing to direct patient service revenue growth.
• Bristol, Rhode Island, was granted a Certificate of Need (CoN) on April 9, 2024, to provide radiation therapy services.
• RI PBRT was granted a CoN on December 10, 2024, to construct and operate a freestanding PBRT system in Johnston, Rhode Island.
• The Proton Beam Radiation Therapy Lease Agreement with Orlando Health was extended for an additional seven years, from April 6, 2026, through April 5, 2033.
• Interest and other income increased by $120,000 in 2025, primarily due to favorable exchange rates for the US dollar against the Mexican peso.
• Remediation efforts for the material weakness in internal controls have commenced, including expanded accounting staff and planned system enhancements.

Negatives

• The company reported a net loss attributable to American Shared Hospital Services of $(1,553,000) in 2025, a significant decline from net income of $2,186,000 in 2024.
• Total revenue decreased by 0.9% in 2025 compared to 2024.
• The leasing segment's revenue decreased by $3,076,000 in 2025.
• Gamma Knife procedure volume decreased by 13.6% in 2025.
• PBRT procedure volume decreased by 21.1% in 2025.
• The company's working capital position deteriorated significantly, moving from a surplus of $15,853,000 in 2024 to a deficit of $5,724,000 at December 31, 2025.
• Cash and cash equivalents decreased by $7,563,000 in 2025.
• The company is not in compliance with its minimum fixed-charge coverage ratio, maximum funded debt-to-EBITDA ratio, and Minimum Cash Covenant ($5,000,000) under the Credit Agreement with Fifth Third Bank as of September 30, 2025, and December 31, 2025.
• Fifth Third Bank has issued a notice of Event of Default and suspended the Revolving Loan Commitment, reserving all rights, including acceleration of payment obligations.
• The Credit Agreement with Fifth Third Bank matures on April 9, 2026, and the company does not have sufficient cash on hand to repay the facilities at maturity without an extension.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• A material weakness in internal control over financial reporting was identified as of December 31, 2025, due to insufficient personnel and resources.
• Physician turnover at the Rhode Island facilities impacted direct patient service volumes during 2025.
• Equipment downtime in Peru for a Gamma Knife upgrade in July 2025 negatively impacted direct patient service volumes.
• Three Gamma Knife contracts expired in the fourth quarter of 2024, first quarter of 2025, and second quarter of 2025, contributing to revenue decline in the leasing segment.
• The company reduced its estimate of salvage value for all seven Gamma Knife units to $0 as of December 31, 2024, and recognized a $3,084,000 impairment loss in 2024.

Risks

• The company may be unable to secure additional debt financing or extend its current credit agreements, negatively impacting operations and profitability.
• An event of default under the Credit Agreements could lead to suspended borrowing abilities, accelerated payment obligations, and seizure of company assets.
• The company's liquidity position and the potential acceleration of payment obligations under the Credit Agreements raise substantial doubt about its ability to continue as a going concern.
• The existence of substantial doubt regarding the company's ability to continue as a going concern may adversely affect its ability to obtain additional financing, its stock price, and relationships with third parties.
• Debt agreements contain restrictive covenants that limit the company's flexibility in operating its business, including limitations on liens, indebtedness, mergers, dividends, and capital expenditures.
• Failure to successfully diversify its business model beyond Gamma Knife and PBRT could lead to declining revenues and profitability as existing contracts expire.
• Federal reimbursement rates for Gamma Knife treatments may not provide an adequate return on investment, and future reductions could adversely affect revenues and financial results.
• Revenue sharing contracts are subject to payor-mix variability, where a shift to a higher level of government payors could reduce the average reimbursement rate per treatment.
• The substantial capital investment required for each site (Gamma Knife $3.0M-$4.5M, PBRT $30M-$50M) may not be fully recovered, or a satisfactory return on investment may not be earned.
• The company may be obligated to remove equipment at the end of lease terms, incurring Asset Retirement Obligations (ARO) and removal costs.
• The market for the Gamma Knife is limited and potentially mature, making it difficult to place additional units.
• Existing contracts with customers are fixed in length, and there is no assurance that customers will extend them beyond the term.
• Failure to remediate the material weakness in internal control over financial reporting could adversely affect timely and accurate financial reporting, investor confidence, reputation, and business operations.
• The company's cash flow could become insufficient to service its debt, potentially forcing delays in investments, seeking additional capital, or restructuring/refinancing debt.
• A small number of customers account for a major portion of revenues (two customers accounted for 26% and 31% of total revenue in 2025), and the loss of any significant customer could have a material adverse effect.
• The company may be unable to renew long-term facility leases, requiring costly relocation or closure of facilities.
• The market for the company's services is competitive, and failure to compete effectively against manufacturers and other outsourcing companies could negatively impact business and results of operations.
• Alternatives to the Gamma Knife (other radiosurgery devices, conventional neurosurgery) could lead medical centers to choose other options, impacting utilization and profitability.
• International operations (Peru, Ecuador, Mexico) expose the company to risks such as exchange rate volatility, legal/regulatory uncertainty, political/economic instability, tariffs, and inability to repatriate funds.
• New technology and products could render the company's existing equipment obsolete, making operations uneconomical.
• Any failure, interruption, or breach in security of the company's information technology (IT) infrastructure due to cyber-attacks could cause financial penalties, reputational damage, and legal liability.
• Unfavorable macroeconomic conditions (e.g., inflation, fluctuating interest rates, geopolitical pressures) could negatively impact business, reduce spending on medical equipment, and affect access to capital.
• The potential impairment of the Gamma Knife portfolio and its salvage value could adversely impact financial condition and results of operations (e.g., $3,084,000 impairment in 2024).
• The trading volume of the company's common stock is low, leading to greater price volatility and difficulty for shareholders to sell shares.
• Concentrated ownership by officers, directors, and principal shareholders (Raymond Stachowiak beneficially owns ~23.8%) could limit the influence of other investors.
• The company does not anticipate paying dividends on its common stock in the foreseeable future.
• Uncertainty regarding the implementation and form of the Radiation Oncology Alternative Payment Method (RO APM) or the ROCR Act could significantly alter Medicare payment methodology for radiation oncology services.
• Potential legal proceedings under the Federal False Claims Act or state anti-kickback laws could result in penalties.
• Certificate of Need (CoN) procedures can be expensive and time-consuming, impacting the length of time before services commence and affecting competitive position.
• The company is responsible for obtaining and maintaining licenses for Cobalt 60 radioactive sources for its Gamma Knife units.

Future Outlook

The company expects to construct a LINAC facility in Bristol, Rhode Island, anticipating the first patient in approximately 18 to 24 months. The San Javier facility in Guadalajara, Mexico, is not expected to begin treating patients until mid to late 2026. The freestanding PBRT system in Johnston, Rhode Island, is anticipated to be built and treating its first patient in approximately 36 months. The company is currently in discussions with Fifth Third Bank regarding a potential extension of the maturity of its Credit Agreement, which matures on April 9, 2026. There is ongoing uncertainty regarding the implementation and form of new Medicare payment models like the RO APM or the ROCR Act, which could significantly alter reimbursement for radiation oncology services. The company anticipates recording income tax expense if it operates profitably in the future and plans to continue enhancing its accounting systems and financial reporting processes to address internal control weaknesses. It intends to finance substantially all commitments for Gamma Knife and LINAC equipment totaling $7,884,000.

Management Comments

• "We believe the decrease in PBRT volume during 2025 was due to normal, cyclical fluctuations."
• "We believe it will be able to negotiate an extension to the Credit Agreement, however, if the Company is unable to do so, the Company's liquidity will be adversely impacted and the Company's ability to satisfy all of its commitments over the next twelve months in accordance with their current terms would be jeopardized."
• "Management has determined that the Company's liquidity condition raises substantial doubt about the Company's ability to continue as a going concern, should Fifth Third and DFC accelerate all payment obligations."
• "The Company believes it is in compliance with the federal anti-kickback statute and, to the extent applicable, any state anti-kickback laws."
• "The Company believes it is in substantial compliance with the various rules and regulations that affect its businesses."
• "The Company believes that its employee relations are good."

Industry Context

StockSavvy.ai notes that the company operates in the highly capital-intensive and regulated medical equipment and radiation therapy sector. The strategic shift towards direct patient services and diversification into LINACs and PBRT reflects a broader industry trend to capture more of the value chain and expand treatment offerings. The ongoing uncertainty around Medicare reimbursement models (RO APM, ROCR Act) highlights the significant regulatory risk inherent in the U.S. healthcare market, particularly for providers reliant on government payers. The competition from direct sales by manufacturers like Elekta and other financing entities underscores the need for differentiated business models and strong capital access, which the company's current financial instability may hinder.

Comparison to Industry Standards

• The company's PBRT system at Orlando Health competes with conventional LINAC-based radiation therapy, which is more widely available, with fewer than 50 PBRT centers currently operating in the United States.
• Single treatment room PBRT systems, such as the Mevion S250, cost approximately $30 million to $50 million, significantly less than fourand five-room PBRT programs costing in excess of $120 million, potentially positioning the company to expand PBRT access.
• Conventional LINAC installations cost in the range of approximately $3 million to $4 million, making them a more accessible alternative for many cancer centers.
• The company estimates there are two other companies that actively provide alternative, non-conventional Gamma Knife financing to potential customers, indicating a competitive but niche market.
• The company's non-exclusive relationship with Elekta, the manufacturer of the Leksell Gamma Knife, means it competes with Elekta's direct sales to customers.

Management Changes

Corporate Governance

Legal Proceedings

• There are no material pending legal proceedings involving the company or any of its property.
• The company knows of no legal or administrative proceedings against it contemplated by governmental authorities.

Related Party Transactions

• GK Financing, LLC (GKF), in which the company holds an 81% indirect interest, has a 19% interest owned by GKV Investments, Inc., a wholly-owned U.S. subsidiary of Elekta AG, the manufacturer of the Gamma Knife.
• Significant related party transactions with Elekta include equipment purchases, commitments to purchase and service equipment, and costs to maintain equipment.
• Equipment purchases and de-install costs from related parties totaled $4,412,000 in 2025 and $5,268,000 in 2024.
• Costs incurred to maintain equipment from related parties totaled $978,000 in 2025 and $678,000 in 2024.
• Total related party transactions amounted to $5,390,000 in 2025 and $5,946,000 in 2024.
• Related party commitments to purchase and install two Esprit upgrades, one LINAC, and service related equipment totaled $10,754,000 as of December 31, 2025.
• Related party liabilities (accounts payable, asset retirement obligations, and other accrued liabilities) were $1,887,000 at December 31, 2025, and $2,270,000 at December 31, 2024.
• The company's stand-alone radiation therapy facility in Puebla, Mexico, has a lease with a related party.

Stakeholder Impact

• Shareholders face significant negative impact due to the net loss, substantial liquidity concerns, explicit 'going concern' doubt, and potential stock price volatility. The absence of anticipated dividends and concentrated insider ownership may further limit investor returns and influence.
• Employees may experience uncertainty due to the company's financial instability, although management states that employee relations are good. Stock-based compensation plans are in place, but their value is tied to the company's performance.
• Customers (medical centers and hospitals) could face potential disruptions in services if the company's financial issues lead to an inability to fulfill equipment leasing or service commitments. However, the extension of the Orlando Health PBRT lease provides stability for that customer.
• Suppliers, particularly Fifth Third Bank and DFC, face increased risk due to multiple debt defaults and the 'going concern' doubt. Fifth Third Bank has already suspended the Revolving Loan Commitment, and both lenders could accelerate debt obligations.
• Creditors are at high risk due to the company's non-compliance with debt covenants and the explicit statement that the company would not have sufficient cash to satisfy accelerated payment obligations.

Next Steps

• Negotiate an extension or amendment to the Credit Agreement with Fifth Third Bank to address maturity and covenant defaults.
• Construct a LINAC facility in Bristol, Rhode Island, with anticipated patient treatment in 18-24 months.
• Construct and operate a freestanding PBRT system in Johnston, Rhode Island, with anticipated patient treatment in approximately 36 months.
• Continue efforts to remediate the material weakness in internal control over financial reporting by hiring additional accounting and finance personnel and enhancing systems.
• San Javier (Guadalajara, Mexico) is expected to begin treating patients in mid to late 2026.
• Esprit upgrades and one LINAC installation are anticipated in the second half of 2026 or later.
• Monitor cybersecurity risks and strive to invest in and strengthen the cybersecurity infrastructure.
• Evaluate ASU 2024-03 and ASU 2025-05 to determine their impact on consolidated financial statements.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a net loss, significant cash burn, a working capital deficit, and multiple debt covenant defaults. The 'going concern' doubt, explicitly stated by management and the auditor, indicates a high probability of financial instability or restructuring. While there are some operational expansions, the immediate and critical liquidity issues, coupled with the risk of debt acceleration, make the stock a high-risk investment with substantial downside potential.

Keywords

radiation therapy, Gamma Knife, PBRT, proton beam radiation therapy, medical equipment leasing, direct patient services, SEC filing, 10-K, financial results, debt covenants, going concern, cybersecurity, healthcare technology, oncology, Elekta, Fifth Third Bank, DFC Loan, internal controls, Rhode Island Acquisition, Mexico operations, Ecuador operations, Peru operations